ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.570,82
-0,14%
S&P 500
5.315,79
0,14%
US Dollar vs BRL
5,1148
0,20%
Bitcoin
69.826,21
-2,27%
Brent Oil
82,955
-0,69%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. REGENXBIO Inc (RGNX)

  7. REGENXBIO Inc (RGNX) Notícias

RGNX

REGENXBIO (RGNX)

REGENXBIO Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RGNX
DataHoraFonteTítuloCódigoCompanhia
16/05/202418:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGNXREGENXBIO Inc
14/05/202417:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RGNXREGENXBIO Inc
10/05/202408:05PR Newswire (US)REGENXBIO to Participate in Upcoming Investor ConferencesNASDAQ:RGNXREGENXBIO Inc
08/05/202417:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGNXREGENXBIO Inc
08/05/202417:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGNXREGENXBIO Inc
08/05/202417:05PR Newswire (US)REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
01/05/202408:05PR Newswire (US)REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
24/04/202408:05PR Newswire (US)REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitNASDAQ:RGNXREGENXBIO Inc
28/03/202408:05PR Newswire (US)REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDNASDAQ:RGNXREGENXBIO Inc
27/03/202417:05PR Newswire (US)REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy DaysNASDAQ:RGNXREGENXBIO Inc
08/03/202408:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RGNXREGENXBIO Inc
07/03/202408:03Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:RGNXREGENXBIO Inc
07/03/202401:20PR Newswire (US)REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded WarrantsNASDAQ:RGNXREGENXBIO Inc
06/03/202418:10PR Newswire (US)REGENXBIO Announces Proposed Public Offering of Common StockNASDAQ:RGNXREGENXBIO Inc
05/03/202409:05PR Newswire (US)REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIALNASDAQ:RGNXREGENXBIO Inc
29/02/202418:57PR Newswire (US)REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® TrialNASDAQ:RGNXREGENXBIO Inc
27/02/202418:54Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RGNXREGENXBIO Inc
27/02/202418:05PR Newswire (US)REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
21/02/202409:05PR Newswire (US)REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
07/02/202413:40PR Newswire (US)REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary EndpointNASDAQ:RGNXREGENXBIO Inc
07/02/202409:05PR Newswire (US)REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® TrialNASDAQ:RGNXREGENXBIO Inc
31/01/202409:05PR Newswire (US)REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024NASDAQ:RGNXREGENXBIO Inc
16/01/202416:47PR Newswire (US)REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal DeliveryNASDAQ:RGNXREGENXBIO Inc
10/01/202409:05PR Newswire (US)REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 MeetingNASDAQ:RGNXREGENXBIO Inc
08/01/202409:05PR Newswire (US)U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement LawsuitNASDAQ:RGNXREGENXBIO Inc
29/11/202309:05PR Newswire (US)REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® TrialNASDAQ:RGNXREGENXBIO Inc
08/11/202318:05PR Newswire (US)REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial ResultsNASDAQ:RGNXREGENXBIO Inc
03/11/202319:53PR Newswire (US)REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal DeliveryNASDAQ:RGNXREGENXBIO Inc
01/11/202308:05PR Newswire (US)REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
30/10/202308:05PR Newswire (US)REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual MeetingNASDAQ:RGNXREGENXBIO Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RGNX

Seu Histórico Recente

COIN
LUXBTC
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados